ERBB2 and ovarian carcinoma: The Impact on ovarian cancer cells proliferation was tested by pulsing with tritium marked thymidine (3H-T) following treatment with increasing concentrations of trastuzumab, anti-HER-2 biosimilars, and AVEC.